_edited.png)
miRoncol
A miracle in oncology made possible with miRNA
A potential shared pattern of 12+ cancers
miRoncol identify a presumably shared pattern from 12+ types of solid tumors that are accountable for ~60% of total cancer death today.
Non-invasive and convenient
miRoncol's technology is a blood test that can be prescribed by physicians for regular checkups.
Superior performance
miRoncol's technology can expose signals from early stage cancers accurately while keep false positive rate very low.
More affordable
miRoncol's technology doesn't introduce any new equipememnt. It uses globally available platform PCR that can be much more affordable then alternative solutions and reach more people in need.
miRNA based technology
Discovery of microRNA(miRNA) won the 2024 Nobel Prize in Medicine
Promising biomarkers for disease diagnosis and prognosis
Check out 1-min video about miRNA
Basic Properties
-
Discovered in 1993
-
Short single-stranded nucleatides
-
Stable and detectable in blood
Functions
-
Non-coding RNA
-
Regulate gene expression
-
Abnormal expression profile in cancer patients
Scientific rigor
Publications
Peer-reviewed publications
Noninvasive multi-cancer detection using blood-based cell-free microRNAs
A Novel Blood-Based microRNA Diagnostic Model with High Accuracy for Multi-Cancer Early Detection
Presentations
Poster presentation at the 2024 Early Detection of Cancer Conference
Poster presentation at 2022 Annual Meeting of American Society of Clinical Oncology.​
Poster presentation at the 2024 ASCO Breakthrough and won one abstract award.​
Poster presentation at the 2022 Annual Meeting of American Association for Cancer Research.
Poster presentation at 2023 European Society for Medical Oncology Congress Meeting​
At the 2021 World Conference on Lung Cancer, our study was not only selected for oral presentation, but also highlighted in the Meeting News.​​
Recurring
Real-time
Risk assessment tool
to enable more people to catch early stage cancers in health checkups.
Accurate+Affordable+Accessible
Most early stage solid tumors are incidental findings through various imaging tools instead of cancer screening. Catching cancers early significantly improves treatment outcomes, increases long-term survival rates, and often allows for less invasive and more effective treatment options.
​​
miRoncol is dedicated to bringing a category-defining tool to provide more certainty to people rather than praying for luck to identify their silently growing cancers incidentally.